Beam therapeutics to participate in guggenheim smid cap biotech conference

Cambridge, mass., jan. 30, 2025 (globe newswire) -- beam therapeutics inc. (nasdaq: beam), a biotechnology company developing precision genetic medicines through base editing, today announced that john evans, chief executive officer of beam, plans to participate in a fireside chat during the guggenheim smid cap biotech conference on thursday, february 6, 2025, at 2:30 p.m. et in new york.
SMID Ratings Summary
SMID Quant Ranking